Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
AstraZeneca
McKesson
McKinsey
Colorcon

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Interferon beta-1b - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for interferon beta-1b

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Lund UniversityPhase 4
ALK-Abelló A/SPhase 4
University of CopenhagenPhase 4

See all interferon beta-1b clinical trials

Company Disclosures: US Patents for interferon beta-1b

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial Cetus Corporation (Emeryville, CA) 2039-03-29 RX Orphan company
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial Cetus Corporation (Emeryville, CA) 2004-03-28 RX Orphan company
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial Cetus Corporation (Emeryville, CA) 2003-05-13 RX Orphan company
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial Cetus Corporation (Emeryville, CA) 2005-04-12 RX Orphan company
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial Cetus Corporation (Emeryville, CA) 2002-10-19 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for interferon beta-1b

These patents were identified by searching patent claims

Supplementary Protection Certificates for interferon beta-1b

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016 00058 Denmark   Start Trial PRODUCT NAME: DACLIZUMAB; REG. NO/DATE: EU/1/16/1107 20160705
2016 00058 Denmark   Start Trial PRODUCT NAME: DACLIZUMAB; REG. NO/DATE: EU/1/16/1107 20160705
C0024 Belgium   Start Trial PRODUCT NAME: INTERFERON ALFACON-1; REGISTRATION NO/DATE: EU/1/98/O87/001 19990201
/2016 Austria   Start Trial PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 (MITTEILUNG) 20160705
3 5027-2016 Slovakia   Start Trial PRODUCT NAME: DAKLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160705
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Dow
Mallinckrodt
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.